tbuckley/cabot-search huggingface dataset:
PWE-115 Detection and Characterisation of Colorectal Polyps Using High Definition White Light and I-Scan: Evidence and Delphi Process-Based Consensus Recommendations
Authors: P Bhandari, S Thayalasekaran, N Helmut, R Kiesslich, S Sanduleanu
Journal: Gut (2016)

<h3>Introduction</h3> Electronic imaging technologies such as i-Scan, Narrow Band Imaging (NBI) and Fujinon Intelligence Colour Enhancement (FICE) are increasingly used for polyp detection and characterisation, but to date, their use is limited to expert settings. I-scan is a relatively novel technology. Insufficient literature with i-scan and the lack of RCT’s hinder its implementation in clinical practice. Our goal was to review the current literature on the clinical utility of i-scan and develop evidence-based practical recommendations. <h3>Methods</h3> We conducted a systematic review on the role of high definition white-light (HDWL) and i-Scan colonoscopy for polyp detection and characterisation. A series of evidence-based statements were developed and put through anonymous voting along the lines of a modified Delphi process. A one day consensus meeting was held (June 20, 2015, Milan). Each statement was voted until consensus (i.e &gt;80% agreement) was achieved or rejection agreed. GRADE recommendations were assigned to the agreed statements. <h3>Results</h3> The Consensus Panel consisted of 11 international experts. In total, 11 statements were proposed, of which 9 achieved consensus: HDWL is recommended rather than standard definition (SD) for the detection and characterisation of colorectal polyps; HDWL + i-Scan improves polyp and adenoma detection rates; HDWL + i-Scan are superior to HDWL alone for the optical diagnosis of colorectal polyps; HDWL + i-Scan in expert hands meet the ASGE PIVI standards for the optical diagnosis of diminutive polyps; HDWL+i-Scan in non-expert hands do not meet the ASGE PIVI standards for the optical diagnosis of diminutive polyps; Optical diagnosis of polyps with i-Scan has a learning curve and needs systematic training; The performance of i-Scan for real time characterisation of colorectal polyps is similar to NBI &amp; FICE. Two statements failed to achieve consensus: HDWL alone can be effective for the in-vivo characterisation of polyps in expert hands; The adenoma detection rate is comparable when using HDWL + i-scan versus chromoendoscopy. <h3>Conclusion</h3> The Consensus Panel proposes evidence-based recommendations for the detection and characterisation of colorectal polyps using high-definition white light endoscopy and i-scan, to facilitate implementation of this technology in clinical practice. Areas of uncertainty, controversy and future research needs are addressed. <h3>Disclosure of Interest</h3> None Declared
Precision Benefit Design—Using “Smarter” Deductibles to Better Engage Consumers and Mitigate Cost-Related Nonadherence
Authors: A. Mark Fendrick, Michael E. Chernew
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Outcomes in Children with Severe Aplastic Anemia Receiving Bone Marrow Transplantation from an HLA-Matched Family Donor or Intensive Immunosuppressive Therapy As First-Line Treatment,
Authors: Nao Yoshida, Akira Kikuchi, Ryoji Kobayashi, Hiromasa Yabe, Yoshiyuki Kosaka, Hideki Muramatsu, Yoshiyuki Takahashi, Koji Kato, Ritsuro Suzuki, Akira Ohara, Seiji Kojima
Journal: Blood (2011)
Identifying aggressive prostate cancer foci using a DNA methylation classifier
Authors: Kamilla Mundbjerg, Sameer Chopra, Mehrdad Alemozaffar, Christopher Duymich, Ranjani Lakshminarasimhan, Peter W. Nichols, Manju Aron, Kimberly D. Siegmund, Osamu Ukimura, Monish Aron, ‬Mariana Stern, Parkash Gill, John D. Carpten, Torben F. Ørntoft, Karina D. Sørensen, Daniel J. Weisenberger, Peter A. Jones, Vinay Duddalwar, Inderbir Gill, Gangning Liang
Journal: Genome biology (2017)

Slow-growing prostate cancer (PC) can be aggressive in a subset of cases. Therefore, prognostic tools to guide clinical decision-making and avoid overtreatment of indolent PC and undertreatment of aggressive disease are urgently needed. PC has a propensity to be multifocal with several different cancerous foci per gland.Here, we have taken advantage of the multifocal propensity of PC and categorized aggressiveness of individual PC foci based on DNA methylation patterns in primary PC foci and matched lymph node metastases. In a set of 14 patients, we demonstrate that over half of the cases have multiple epigenetically distinct subclones and determine the primary subclone from which the metastatic lesion(s) originated. Furthermore, we develop an aggressiveness classifier consisting of 25 DNA methylation probes to determine aggressive and non-aggressive subclones. Upon validation of the classifier in an independent cohort, the predicted aggressive tumors are significantly associated with the presence of lymph node metastases and invasive tumor stages.Overall, this study provides molecular-based support for determining PC aggressiveness with the potential to impact clinical decision-making, such as targeted biopsy approaches for early diagnosis and active surveillance, in addition to focal therapy.
Mod-5014, a Long-Acting FVIIa-CTP, Proposing a Novel Prophylactic Treatment Supporting Less Frequent Subcutaneous or Intravenous Injections with a Similar Mechanism of Action to rFVIIa: Proof-of-Concept in Hemophilic Animal Models
Authors: Lior Binder, Ahuva Bar-Ilan, Malka Hoffman, Gili Hart
Journal: Blood (2015)
Insertional Activation of MDS1/EVI1, PRDM16 and SETBP1 in a Successful Chronic Granulomatous Disease (CGD) Gene Therapy Trial.
Authors: Kerstin Schwarzwaelder, Manfred Schmidt, Annette Deichmann, Marion G. Ott, Stefan Stein, Hanno Glimm, Ulrich Siler, Dieter Hoelzer, Reinhard Seger, Manuel Grez, Christof von Kalle
Journal: Blood (2006)
The Relationship between ABO Groups, Factor VIII, von Willebrand Factor Levels and Platelet Function Analysis Using Cone and Plate(let) Analyzer.
Authors: Maria Lourdes Barjas Castro, Aline Crucello, Heloise P. Fernandes, Norma C. Sousa, Joyce M. Annichino-Bizzacchi, Vagner Castro
Journal: Blood (2007)
Employers should not add management objectives to revalidation process, GMC says
Authors: Abi Rimmer
Journal: BMJ (2017)

Employers must not add management objectives to revalidation requirements, a review of the process commissioned by the General Medical Council has said.

In the report, Keith Pearson, chair of both Health Education England and the GMC’s revalidation advisory board, set out 15 recommendations for improving the process.1 Among his recommendations was the suggestion that more should be done to make clear what is and what is not a mandatory part of revalidation.

Pearson said that he had heard concerns from doctors and royal colleges about employers adding requirements for appraisal or revalidation that go beyond those specified by the GMC. “I have been given examples of doctors being asked to carry out specific numbers or types of clinical audits; attend generic training courses; use specific templates or obtain fixed numbers of continuing professional development points before they can be revalidated,” he said. “These are not …
Brief Report: Altered Innate Lymphoid Cell Subsets in Human Lymph Node Biopsy Specimens Obtained During the At‐Risk and Earliest Phases of Rheumatoid Arthritis
Authors: Javier Rodríguez‐Carrio, Janine S. Hähnlein, Tamara H. Ramwadhdoebe, Johanna F. Semmelink, Ivy Y. Choi, Krijn P. van Lienden, Mario Maas, Danielle M. Gerlag, Paul P. Tak, Teunis B. H. Geijtenbeek, Lisa G. M. van Baarsen
Journal: Arthritis & Rheumatology (2016)

Objective Innate lymphoid cells (ILCs) are emerging mediators of immunity, and accumulation of inflammatory ILC populations can occur in inflammatory‐mediated conditions. Since early lymph node (LN) activation has been shown in rheumatoid arthritis (RA), we aimed to investigate the frequency and distribution of ILCs in LN biopsy specimens obtained during the earliest phases of RA. Methods Twelve patients with early RA, 12 individuals with IgM rheumatoid factor and/or anti–citrullinated protein antibodies without arthritis (RA risk group), and 7 healthy controls underwent ultrasound‐guided inguinal LN biopsy. ILC subsets and the expression of vascular cell adhesion molecule (VCAM) and intercellular adhesion molecule (ICAM) by LN endothelial cells and fibroblasts were analyzed by flow cytometry. Results Although no differences in the frequencies of total ILCs (Lin−CD45 +/low CD127+) were found, the distribution of the ILC subpopulations differed among groups. RA patients showed lower numbers of lymphoid tissue–inducer (LTi) cells (c‐Kit+NKp44− ILCs) and increased ILC1 (c‐Kit−NKp44− ILCs) and ILC3 (c‐Kit+NKp44+ ILCs) numbers compared with controls ( P &lt; 0.001, P &lt; 0.050, and P &lt; 0.050, respectively). Individuals at risk of RA exhibited an increased frequency of ILC1 compared with controls ( P &lt; 0.01). LTi cells paralleled the expression of adhesion molecules on endothelial cells and fibroblasts. Conclusion Our findings indicate that during the at‐risk and earliest phases of RA, the ILC distribution in LN changes from a homeostatic profile toward a more inflammatory profile, thereby providing evidence of a role for ILCs in RA pathogenesis.
Role of NF-E2 Related Factor 2 (NRF2) on Chemotherapy Resistance in Acute Myeloid Leukemia (AML) and the Effect of Pharmacological Inhibition of NRF2
Authors: Sreeja Karathedath, Bharathi M Rajamani, Savitha Varatharajan, Ajay Abraham, Vikram Mathews, Shaji R Velayudhan, Poonkuzhali Balasubramanian
Journal: Blood (2015)
Forkhead transcription factor Foxo-3a induces terminal differentiation of erythroid precursors by induction of BTG1, a co-activator of protein arginine methyl transferase 1.
Authors: TB van Dijk, WJ Bakker, M Blazquez, A Kolbus, PJ Coffer, J Besooyen, P Steinlein, H Beug, B Lowenberg, MM von Lindern
Journal: Blood (2002)
Fc Gamma Receptor 3a Genotype Predicts Overall Survival for Follicular Lymphoma Patients Treated On Southwest Oncology Group Trials with Combined Monoclonal Antibody Plus Chemotherapy but Not Chemotherapy Alone.
Authors: Daniel O. Persky, David Dornan, Bryan H Goldman, Rita M. Braziel, Richard I Fisher, Michael LeBlanc, David G. Maloney, Thomas P. Miller, Oliver W. Press, Lisa M. Rimsza
Journal: Blood (2009)
The flame is almost extinguished
Authors: Kaustubh G Joshi
Journal: BMJ (2017)

“I can’t take it anymore.” “I don’t know how I can go on.” “I don’t want to go to work.” “I think I’m done.” These words could represent a patient’s distress, but they were uttered by a physician colleague and friend. My friend didn’t have clinical depression; he was experiencing burnout.

Physician burnout has become ubiquitous. It is …
Clinical Significance of Granulocytic Sarcoma in Patients with Acute Myeloid Leukemia.
Authors: Hiroaki Shimizu, Takayuki Saitoh, Takumi Hoshino, Naoko Hatsumi, Satoru Takada, Hiroyuki Irisawa, Akihiko Yokohama, Takahiro Jimbo, Hiroshi Handa, Takafumi Matsushima, Toru Sakura, Norifumi Tsukamoto, Masamitsu Karasawa, Shuichi Miyawaki
Journal: Blood (2009)
Lenalidomide Enhancement of NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Is Mediated by Granzyme B and FasL and Is Associated with Modification of SHIP-1, PLC-g2 and pERK and Enhanced Chemokine Production.
Authors: Lei Wu, Mary Adams, Peter Schafer, George Muller, David Stirling, Blake J. Bartlett
Journal: Blood (2007)
Nur77 and Nurr1, Two Novel Players In MSC Migration and Immune Function.
Authors: Marijke Maijenburg, Christian Gilissen, Joris Veltman, Marion Kleijer, Cris Mudde-Jadra, Kees Weijer, Anja ten Brinke, Claudia van Tiel, Carlie de Vries, Ellen van der Schoot, Carlijn Voermans
Journal: Blood (2010)
Treatment of recurrent Clostridium difficile infection using fecal microbiota transplantation in patients with inflammatory bowel disease
Authors: Krista M. Newman, Kevin M. Rank, Byron P. Vaughn, Alexander Khoruts
Journal: Gut Microbes (2017)

We recently compared results of fecal microbiota transplantation (FMT) in patients with refractory, recurrent Clostridium difficile infection (rCDI), with and without underlying inflammatory bowel disease (IBD). Here we extend this cohort and analyze outcomes in greater detail by subtype of IBD. We find that FMT is generally effective in breaking the cycle of CDI recurrence, but its effects on overall IBD progression are much less predictable. We discuss several challenges intrinsic to this complex clinical situation and outline the next steps that can address these challenges going forward.
A Prospective, Observational Study on the Safety and Effectiveness of Rituximab Plus Chemotherapy As the First-Line Treatment of Diffuse Large B-Cell Lymphoma
Authors: Jifeng Feng, Jianqiu Wu, Yongping Song, Liping Su, Mingzhi Zhang, Wei Li, Yu Hu, Xiaohong Zhang, Yuhuan Gao, Ru Feng, Wei Wang, Zuoxing Niu, Jiewen Peng, Xiaolin Li, Xuenong Ouyang, Changing Wu, Weijing Zhang, Yun Zeng, Zhen Xiao, Yingmin Liang, Yongzhi Zhuang, Jishi Wang, Zimin Sun, Hai Bai, Tongjian Cui
Journal: Blood (2014)
Can you cause inflammatory bowel disease with fecal transplantation? A 31-patient case-series of fecal transplantation using stool from a donor who later developed Crohn's disease
Authors: Monika Fischer, Mohamad Bittar, Eliseo Papa, Zain Kassam, Mark Smith
Journal: Gut Microbes (2017)

Despite rigorous donor screening, the possibility that transmission of chronic inflammatory disorders could occur as a consequence of fecal microbiota transplantation (FMT) remains a serious potent...
Inhibition of Hematopoietic Progenitor Cells by CD4+ T Cells Specific for an Endogenous Peroxisomal Protein, DRS-1: A Possible Mechanism for Bone Marrow Failure in Individuals Carrying HLA-DR15.
Authors: Xingmin Feng, Tatsuya Chuhjo, Xuzhang Lu, Hiroyuki Takamatsu, Chiharu Sugimori, Akiyoshi Takami, Shinji Nakao
Journal: Blood (2004)
Statins and outcomes in patients with pneumonia
Authors: Eric M Mortensen, Marcos I Restrepo, Laurel A Copeland, Mary Jo V Pugh, Antonio Anzueto
Journal: BMJ (2006)

<h3>Abstract</h3> <h3>Objectives</h3> Patients with diabetes are at high risk for polypharmacy (ie, use of multiple medications) for treatment of diabetes, associated comorbidities and other coexisting conditions. This study aims to estimate the prevalence of polypharmacy and factors associated with polypharmacy among adult patients with diabetes. <h3>Methods</h3> A cross-sectional retrospective observational study of adults with diabetes, who visited the outpatient clinic of a tertiary teaching hospital in Saudi Arabia, was conducted. Data were extracted from the Electronic Health Record database for a period of 12 months (January–December 2016). Polypharmacy was defined as the cumulative use of five or more medications. Polypharmacy among adults with diabetes was measured by calculating the average number of medications prescribed per patient. A multivariable logistic regression model was used to examine the factors associated with polypharmacy. <h3>Results</h3> A total of 8932 adults with diabetes were included in this study. Of these, nearly 78% had polypharmacy which was more likely among women as compared with men and more likely among older adults (age ≥60 years) as compared with the adults. Also, polypharmacy was two times as likely among patients with coexisting cardiovascular conditions (adjusted OR (AOR)=2.89; 95% CI 2.54 to 3.29), respiratory disease (AOR=2.42; 95% CI 1.92 to 3.03) and mental health conditions (AOR=2.19; 95% CI 1.74 to 2.76), and three times as likely among patients with coexisting musculoskeletal disease (AOR=3.16; 95% CI 2.31 to 4.30) as compared with those without these coexisting chronic conditions categories. <h3>Conclusions</h3> Polypharmacy is common among patients with diabetes, with an even higher rate in older adults patients. Healthcare providers can help in detecting polypharmacy and in providing recommendations for simplifying medication regimens and minimising medications to enhance the outcome of diabetes care.
Attenuated Preemptive Therapy Against Cytomegalovirus (CMV) Reactivation/Disease Consisting of a Higher Cutoff Point and a Lower Initial Dose of Ganciclovir after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with an HLA-Identical Sibling Donor.
Authors: Yasushi Onishi, Shin-ichiro Mori, Shigeru Kusumoto, Daigo Akahane, Kyoko Sugimoto, Yoshiki Terada, Sung-Won Kim, Masahiro Kami, Yuji Heike, Ryuji Tanosaki, Kensei Tobinai, Yoichi Takaue
Journal: Blood (2004)
Highly Efficient mRNA- and cDNA-Based Transient Gene Delivery into Human Progenitor Cells.
Authors: Jochen Greiner, Jan Torzewski, Peter Ponsaerts, Markus T. Rojewski, Desiree Kronawitter, Hubert Schrezenmeier, Vinzenz Hombach, Hartmut Dohner, Michael Schmitt, Markus Wiesneth, Oliver Zimmermann, Juliane M. Wiehe
Journal: Blood (2006)
Residual rectal cancer after preoperative radiochemotherapy (ypT1-2): An indication for local excision instead of radical surgery?
Authors: Thilo Sprenger, Hilka Rothe, Lena-Christin Conradi, Kia Homayounfar, Tim Beissbarth, B. Michael Ghadimi, Torsten Liersch
Journal: Journal of Clinical Oncology (2014)

546 Background: Preoperative radiochemotherapy (RCT) followed by total mesorectal excision (TME) has improved local tumor control and led to a significant tumor downstaging. For patients with pathologic complete response (ypT0) as well as residual tumor restricted only to the bowel wall (ypT1-2) local excision has increasingly been discussed to avoid significant morbidity and functional deficits associated with TME. Therefore we investigated the incidence, distribution and tumor-related localization of mesorectal lymph node (LN) metastases in TME specimens with ypT0, ypT1-2 and ypT3-4 rectal cancers, respectively. Methods: TME specimens from 81 patients with locally advanced rectal cancer treated with neoadjuvant RCT within the phase III German Rectal Cancer Trial CAO/ARO/AIO-04 were evaluated. The entire mesorectal compartment was screened microscopically after complete paraffin embedding. The number and localization of all detectable LN metastases was specified in relation to the primary tumor. Results: Whereas 50 patients (62%) had ypT3-4 carcinomas after neoadjuvant RCT 20 patients (25%) presented with residual tumor within the bowel wall (ypT1-2). 11 patients (14%) had pathologic complete response (ypT0). 28 ± 13.7 LN were detected per specimen. 25 patients (31%) had residual LN metastases after RCT. Although the incidence was higher in the ypT3-4 group (40% ypN+) still 25% of patients in the ypT1-2 group had a mean number of 2.2 residual LN metastases. 55% of these metastases were located afar from the primary lesion in the proximal mesorectum. No patient with ypT0 status had residual LN metastases. Conclusions: Even in patients with good response and tumors restricted only to the bowel wall (ypT1-2) after RCT there is a considerable risk for residual LN metastases. The majority of metastases were located clearly outside the tumor region. Local excision of residual rectal cancer would be accompanied by a higher rate of local failure and radical surgery with TME should remain the standard treatment in those patients.
Stiffness‐Controlled Thermoresponsive Hydrogels for Cell Harvesting with Sustained Mechanical Memory
Authors: Xingliang Fan, Lu Zhu, Ke Wang, Bingjie Wang, Yaozu Wu, Wei Xie, Chengyu Huang, Barbara Pui Chan, Yanan Du
Journal: Advanced Healthcare Materials (2017)

Most mechanobiological investigations focused on in situ mechanical regulation of cells on stiffness‐controlled substrates with few downstream applications, as it is still challenging to harvest and expand mechanically primed cells by enzymatic digestion (e.g., trypsin) without interrupting cellular mechanical memory between passages. This study develops thermoresponsive hydrogels with controllable stiffness to generate mechanically primed cells with intact mechanical memory for augmented wound healing. No significant cellular property alteration of the fibroblasts primed on thermoresponsive hydrogels with varied stiffness has been observed through thermoresponsive harvesting. When reseeding the harvested cells for further evaluation, softer hydrogels are proven to better sustain the mechanical priming effects compared to rigid tissue culture plate, which indicates that both the stiffness‐controlled substrate and thermoresponsive harvesting are required to sustain cellular mechanical memory between passages. Moreover, epigenetics analysis reveals that thermoresponsive harvesting could reduce the rearrangement and loss of chromatin proteins compared to that of trypsinization. In vivo wound healing using mechanically primed fibroblasts shows featured epithelium and sebaceous glands, which indicates augmented skin recovery compared with trypsinized fibroblasts. Thus, the thermoresponsive hydrogel‐based cell harvesting system offers a powerful tool to investigate mechanobiology between cell passages and produces abundant cells with tailored mechanical priming properties for cell‐based applications.
Optical Barcoding for Single-Clone Tracking to Study Tumor Heterogeneity
Authors: Malte Mohme, Cecile L. Maire, Kristoffer Riecken, Svenja Zapf, Tim Aranyossy, Manfred Westphal, Katrin Lamszus, Boris Fehse
Journal: Molecular Therapy (2017)

Intratumoral heterogeneity has been identified as one of the strongest drivers of treatment resistance and tumor recurrence. Therefore, investigating the complex clonal architecture of tumors over time has become a major challenge in cancer research. We developed a new fluorescent "optical barcoding" technique that allows fast tracking, identification, and quantification of live cell clones in vitro and in vivo using flow cytometry (FC). We optically barcoded two cell lines derived from malignant glioma, an exemplary heterogeneous brain tumor. In agreement with mathematical combinatorics, we demonstrate that up to 41 clones can unambiguously be marked using six fluorescent proteins and a maximum of three colors per clone. We show that optical barcoding facilitates sensitive, precise, rapid, and inexpensive analysis of clonal composition kinetics of heterogeneous cell populations by FC. We further assessed the quantitative contribution of multiple clones to glioblastoma growth in vivo and we highlight the potential to recover individual viable cell clones by fluorescence-activated cell sorting. In summary, we demonstrate that optical barcoding is a powerful technique for clonal cell tracking in vitro and in vivo, rendering this approach a potent tool for studying the heterogeneity of complex tissues, in particular, cancer.